Edition:
India

Ra Pharmaceuticals Inc (RARX.OQ)

RARX.OQ on NASDAQ Stock Exchange Global Market

46.71USD
20 Nov 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$46.71
Open
$46.65
Day's High
$46.77
Day's Low
$46.52
Volume
225,221
Avg. Vol
270,837
52-wk High
$47.35
52-wk Low
$13.73

Latest Key Developments (Source: Significant Developments)

Ra Pharmaceuticals Q3 Loss Per Share $0.55
Thursday, 7 Nov 2019 

Ra Pharmaceuticals Inc ::RA PHARMACEUTICALS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.55.Q3 EARNINGS PER SHARE ESTIMATE $-0.50 -- REFINITIV IBES DATA.AS OF SEPTEMBER 30, 2019, RA PHARMA REPORTED TOTAL CASH AND CASH EQUIVALENTS OF $292.6 MILLION.RA PHARMACEUTICALS- EXPECTS CASH,CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND OPERATING EXPENSES & CAPEX REQUIREMENTS THROUGH AT LEAST END OF 2021.  Full Article

Ra Pharmaceuticals - If Deal Is Terminated, Co May Be Required To Pay UCB S.A. A Termination Fee Of $75 Mln In Cash
Thursday, 10 Oct 2019 

Oct 10 (Reuters) - Ra Pharmaceuticals Inc ::RA PHARMACEUTICALS - IF DEAL IS TERMINATED UNDER CERTAIN CIRCUMSTANCES, CO MAY BE REQUIRED TO PAY UCB S.A. A TERMINATION FEE OF $75 MILLION IN CASH.  Full Article

Ra Pharma Receives Orphan Drug Designation From The U.S. FDA For Zilucoplan For The Treatment Of Myasthenia Gravis
Wednesday, 4 Sep 2019 

Sept 4 (Reuters) - Ra Pharmaceuticals Inc ::RA PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION FROM THE U.S. FDA FOR ZILUCOPLAN FOR THE TREATMENT OF MYASTHENIA GRAVIS.  Full Article

Ra Pharmaceuticals Earns Clinical Development Milestone For Oral Macrocyclic Peptide Candidate
Wednesday, 21 Aug 2019 

Aug 21 (Reuters) - Ra Pharmaceuticals Inc ::RA PHARMACEUTICALS EARNS CLINICAL DEVELOPMENT MILESTONE FOR ORAL MACROCYCLIC PEPTIDE CANDIDATE TARGETING CARDIOVASCULAR INDICATION UNDER AGREEMENT WITH MERCK.RA PHARMACEUTICALS INC - MARKS SECOND COMPOUND FROM RA'S EXTREME DIVERSITY™ PLATFORM TO ENTER CLINICAL TRIALS.RA PHARMACEUTICALS INC - EARNED A CLINICAL DEVELOPMENT MILESTONE UNDER ITS COLLABORATION AGREEMENT WITH MERCK.  Full Article

Ra Pharmaceuticals Reports Second Quarter 2019 Financial Results
Wednesday, 7 Aug 2019 

Aug 7 (Reuters) - Ra Pharmaceuticals Inc ::RA PHARMACEUTICALS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.52.Q2 EARNINGS PER SHARE ESTIMATE $-0.49 -- REFINITIV IBES DATA.INITIATION OF SINGLE, PIVOTAL, 12-WEEK, PHASE 3 GMG CLINICAL TRIAL ON TRACK FOR SECOND HALF OF 2019.INITIATION OF MULTI-CENTER, PHASE 2 IMNM CLINICAL TRIAL ON TRACK FOR SECOND HALF OF 2019.NO REVENUE EARNED IN Q2 OF 2019 OR SAME PERIOD IN 2018.AS OF JUNE 30, 2019, RA PHARMA REPORTED TOTAL CASH AND CASH EQUIVALENTS OF $173.6 MILLION.RA PHARMA - EXPECTS CASH EQUIVALENTS, FOLLOW-ON OFFERING PROCEES, TO SUFFICIENTLY FUND OPERATING EXPENSES REQUIREMENTS THROUGH AT LEAST END OF 2021.  Full Article

Camurus And Ra Pharmaceuticals Announce License Agreement
Tuesday, 16 Jul 2019 

July 16 (Reuters) - Camurus AB ::RA PHARMACEUTICALS AND CAMURUS ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR FLUIDCRYSTAL® EXTENDED RELEASE FORMULATION OF ZILUCOPLAN.RA PHARMACEUTICALS AND CAMURUS TODAY ANNOUNCED EXCLUSIVE WORLDWIDE LICENSE AGREEMENT FOR USE OF CAMURUS'S PROPRIETARY FLUIDCRYSTAL TECHNOLOGY TO DEVELOP, MANUFACTURE, AND COMMERCIALIZE LONG-ACTING FORMULATION OF ZILUCOPLAN.UNDER AGREEMENT, CAMURUS WILL RECEIVE AN UPFRONT PAYMENT OF $2 MILLION AND IS ELIGIBLE TO RECEIVE UP TO $14.5 MILLION IN DEVELOPMENT MILESTONES AND OTHER LICENSE PAYMENTS, UP TO $55 MILLION IN SALES MILESTONES.  Full Article

Ra Pharmaceuticals Posts Q1 Loss Per Share of $0.45
Thursday, 9 May 2019 

May 9 (Reuters) - Ra Pharmaceuticals Inc ::RA PHARMACEUTICALS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $0.45.Q1 EARNINGS PER SHARE ESTIMATE $-0.48 -- REFINITIV IBES DATA.  Full Article

Ra Pharma Announces Completion Of End-Of-Phase 2 Interactions With FDA, Design Of Pivotal Phase 3 gMG Study
Tuesday, 9 Apr 2019 

April 9 (Reuters) - Ra Pharmaceuticals Inc ::RA PHARMACEUTICALS ANNOUNCES COMPLETION OF END-OF-PHASE 2 INTERACTIONS WITH FDA AND DESIGN OF PIVOTAL PHASE 3 GMG STUDY.RA PHARMACEUTICALS INC - ALIGNMENT WITH FDA ON A SINGLE, PIVOTAL, 12-WEEK, PLACEBO-CONTROLLED, PHASE 3 CLINICAL TRIAL TO INITIATE IN SECOND HALF OF 2019.RA PHARMACEUTICALS - ALIGNMENT WITH FDA ON A SINGLE, PIVOTAL, 12-WEEK, PLACEBO-CONTROLLED, PHASE 3 CLINICAL TRIAL TO INITIATE IN SECOND HALF OF 2019.  Full Article

Ra Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Tuesday, 11 Dec 2018 

Dec 10 (Reuters) - Ra Pharmaceuticals Inc ::RA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.RA PHARMACEUTICALS - INTENDS TO OFFER & SELL $100 MILLION OF ITS COMMON STOCK IN UNDERWRITTEN PUBLIC OFFERING.RA PHARMACEUTICALS - INTENDS TO USE NET PROCEEDS FROM OFFERING, IN ADDITION TO EXISTING CASH RESOURCES, TO FUND CLINICAL DEVELOPMENT OF ZILUCOPLAN.  Full Article

Ra Pharmaceuticals Receives Development Milestone Payment Under Agreement With Merck
Thursday, 6 Dec 2018 

Dec 6 (Reuters) - Ra Pharmaceuticals Inc ::RA PHARMACEUTICALS RECEIVES DEVELOPMENT MILESTONE PAYMENT UNDER AGREEMENT WITH MERCK.RA PHARMACEUTICALS INC - RECEIVED A DEVELOPMENT MILESTONE PAYMENT UNDER ITS COLLABORATION AGREEMENT WITH MERCK, KNOWN AS MSD OUTSIDE US AND CANADA.RA PHARMACEUTICALS INC - CO ELIGIBLE TO EARN UP TO $59 MILLION IN ADDITIONAL MILESTONE PAYMENTS FROM MERCK.RA PHARMACEUTICALS - ALSO ELIGIBLE TO RECEIVE LOW-TO-MID SINGLE DIGIT PERCENTAGE ROYALTIES ON FUTURE SALES OF COMPOUNDS RESULTING FROM COLLABORATION.  Full Article

Deals of the day-Mergers and acquisitions

Oct 10 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Thursday: